Lecigon (Entacapone, Levodopa, Carbidopa Monohydrate)

Levodopa crosses the blood‑brain barrier and is converted to dopamine. Carbidopa inhibits peripheral decarboxylation of levodopa, increasing its central availability. Entacapone blocks the COMT enzyme, slowing levodopa metabolism and prolonging its plasma half‑life, resulting in more stable dopaminergic stimulation.

The specific dose and dosing schedule of Lecigon are determined by the prescribing clinician based on the individual patient's disease severity, response to therapy and tolerability. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety of Lecigon in pregnancy and lactation has not been established. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

Enquiries for Lecigon can be submitted via the product page on gnhindia.com. Provide the required quantity and institutional credentials. GNH India will verify the buyer, then respond with pricing, availability, shipping details and any necessary import documentation.

Lecigon combines levodopa with carbidopa and the COMT inhibitor entacapone, offering longer and more consistent levodopa exposure than levodopa/carbidopa alone. Compared with other COMT inhibitors, entacapone provides a well‑characterized safety profile and is often used when patients experience wearing‑off on standard levodopa therapy.

Lecigon tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Lecigon is taken orally, usually with food to reduce gastrointestinal discomfort. The tablets are swallowed whole with a glass of water. The exact timing relative to meals and other Parkinson's medications is determined by the treating physician.

Serious risks include dyskinesia, severe hypotension, hallucinations, neuroleptic malignant syndrome, severe liver dysfunction and rare blood disorders such as agranulocytosis. Patients should be monitored regularly for these events, and any sudden or severe symptoms should prompt immediate medical evaluation.

Lecigon is contraindicated in patients with known hypersensitivity to levodopa, carbidopa, entacapone or any excipients, and in those taking non‑selective MAO inhibitors. Caution is also advised for individuals with severe hepatic or renal impairment, uncontrolled cardiovascular disease, or a history of melanoma.